Data di Pubblicazione:
2001
Citazione:
CLX-0901 Calyx Therapeutics / D. Barlocco. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 2:5(2001), pp. 650-653.
Abstract:
Calyx Therapeutics is developing the insulin sensitizer, CLX-0901, as an antidiabetic agent. CLX-0901 is the synthetic analog of CLX-0900 which was originally isolated from a plant source. Phase I and toxicological studies indicate that the compound is safe and well tolerated [363764]. As of March 2001, phase II studies had commenced [402737]. Other antidiabetics being investigated by Calyx include CLX-0301, CLX-0921, CLX-0940, CLX-0100 and CLX-0101.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
D. Barlocco
Link alla scheda completa: